Identification of Specific Biomarkers and Pathways in the Treatment Response of Infliximab for Inflammatory Bowel Disease: In-Silico Analysis
Background: Inflammatory bowel disease (IBD) is characterized by chronic inflammation of the gastrointestinal tract. In biological therapy, infliximab became the first anti-tumor necrosis factor (TNF) agent approved for IBD. Despite this success, infliximab is expensive, often ineffective, and assoc...
Main Authors: | Rachid Kaddoura, Hardik Ghelani, Fatma Alqutami, Hala Altaher, Mahmood Hachim, Reem Kais Jan |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-03-01
|
Series: | Life |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-1729/13/3/680 |
Similar Items
-
Early infliximab antibody testing does not prevent infusion reactions when reinitiating infliximab
by: Joseph D. Feuerstein
Published: (2016-08-01) -
Safety profile and side effects of infliximab and adalimumab in inflammatory bowel disease at a referral center in northeastern Brazil
by: Joelma Aurélio de Sousa Santos, et al.
Published: (2024-02-01) -
Inflammatory Bowel Disease Patients’ Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience
by: Clotilde Remy, et al.
Published: (2022-12-01) -
In Silico Analysis of Publicly Available Transcriptomic Data for the Identification of Triple-Negative Breast Cancer-Specific Biomarkers
by: Rachid Kaddoura, et al.
Published: (2023-02-01) -
Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations
by: Gemma Burdge, et al.
Published: (2022-09-01)